CSL vs CBA: comparing Australia’s two largest companies
We examine the fundamentals behind Australia’s two largest publicly listed companies: CSL and CBA.
CBA and CSL share prices: a comparative approach
A number of people have joked that CSL’s share price can only go up.
And after the stock’s recent run up – which saw it briefly become Australia’s most valuable publicly listed company – people may be closer to believing that joke as a truth than ever before.
Of course, as with all things in the market, CSL has no more certainty of continuing its rise than any other investment. Past results, are never an indicator of future performance, investors should remember.
Such an idea may be more pronounced right now due to the fact that markets remain volatile, the full economic impact of the Coronavirus hard to quantify; and equities – both locally and abroad – currently trade at all-time highs.
Even when considering that, as both CBA and CSL continue to run higher, it's worth examining just how both companies got to where they are today.
For one, both companies share an interesting history: one of privatisation.
CSL, originally named Commonwealth Serum Laboratories, was publicly listed on the ASX in 1994. Back then, the ‘fledgling’ biotech had revenues of just $193 million and since then CSL’s share price has delivered a compound annual return of around 25%.
In that sense, CSL’s recent but impressive performance and its place in the spotlight is really nothing new.
Commonwealth Bank of Australia, founded by Australia’s government in 1911, was taken private in 1996. Looking at the bank’s oldest publicly available Annual Report we see that CBA touted FY97 operating revenues of $9.5 billion, against earnings (NPAT) of $1.078 billion.
Things have changed significantly since then, mind you.
The CBA share price is currently trading close to all-time-highs, on a FY19 earnings multiple of 15x. CBA also has cemented its position as Australia’s largest bank, with its keen focus on retail banking continuing to pay off.
As part of its most recent interim results, the bank reported operating income of $12,416 million, against a cash NPAT of $4,477 million. The bank also announced an Interim Dividend of $2.00 per share.
CSL, though not as profitable in absolute terms as CBA, is growing significantly faster than its banking giant counterpart.
Indeed, if Australia’s banking industry is understood to be under siege – CSL inhabits what looks to be an almost diametrically opposed industry: Demand for CSL’s products, centrally its immunoglobulin (IG) portfolio is growing, and rapidly!
'CSL is well positioned for sustainable growth,’ says the company’s CEO, Paul Perreault.
‘Exceptional demand continues for our differentiated therapies. We expect to again outpace the market in expanding plasma collections and our objective to open 40 new collection centres this financial year is on track.’
Such claims look well reflected in the biotech’s recent H1 and its current valuation: here, CSL reported sales and service revenue of US$4,709 million (+8%) against earnings (NPAT) of US$1,248 million (+11%). The biotech giant also bumped up its Interim Dividend and upgraded its full-year earnings outlook. CSL is now expecting NPAT growth in the 10-13% range.
The company previously expected FY20 earnings growth to come in at just 7-10%.
All of this has taken a toll on valuation, mind you. At its current share price CSL is trading at a significant premium to the market, at 53x FY19 earnings. Expensive yes, but an expense investors have been willing to pay for in the last year. In the last 12-months CSL has seen its share price rise an astounding 82%. CBA, by comparison has risen just 22% – still making it the best performing of the big four banks, though.
Finally, at the time of writing, CBA claimed the illustrious title of Australia’s largest company, with a market capitalisation of $155.52 billion.
CSL trailed that just slightly, touting a market capitalisation $153.72 billion.
IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.
The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.
Please see important Research Disclaimer.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.